High molecular mass assemblies of amyloid-b oligomers bind prion protein in patients with Alzheimer’s disease

Alzheimer’s disease is the most common form of dementia and the generation of oligomeric species of amyloid-b is causal to the initiation and progression of it. Amyloid-b oligomers bind to the N-terminus of plasma membrane-bound cellular prion protein (PrP) initiating a series of events leading to synaptic degeneration. Composition of bound amyloid-b oligomers, binding regions within PrP, binding affinities and modifiers of this interaction have been almost exclusively studied in cell culture or murine models of Alzheimer’s disease and our knowledge on PrP-amyloid-b interaction in patients with Alzheimer’s disease is limited regarding occurrence, binding regions in PrP, and size of bound amyloid-b oligomers. Here we employed a PrPamyloid-b binding assay and size exclusion chromatography on neuropathologically characterized Alzheimer’s disease and non-demented control brains (n = 15, seven female, eight male, average age: 79.2 years for Alzheimer’s disease and n = 10, three female, seven male, average age: 66.4 years for controls) to investigate amyloid-b-PrP interaction. PrP-amyloid-b binding always occurred in Alzheimer’s disease brains and was never detected in non-demented controls. Neither expression level of PrP nor known genetic modifiers of Alzheimer’s disease, such as the PrP codon 129 polymorphism, influenced this interaction. In Alzheimer’s disease brains, binding of amyloid-b to PrP occurred via the PrP N-terminus. For synthetic amyloid-b42, small oligomeric species showed prominent binding to PrP , whereas in Alzheimer’s disease brains larger protein assemblies containing amyloid-b42 bound efficiently to PrP . These data confirm Alzheimer’s disease specificity of binding of amyloid-b to PrP via its N-terminus in a large cohort of Alzheimer’s disease/control brains. Differences in sizes of separated protein fractions between synthetic and brain-derived amyloid-b binding to PrP suggest that larger assemblies of amyloid-b or additional non-amyloid-b components may play a role in binding of amyloid-b42 to PrP C in Alzheimer’s disease.